We’re Here To Solve Your Biggest Protein Challenges
Horsholm, Denmark, June 8, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]
Expres2ion Biotechnologies is mentioned in the Swedish newspaper Affärstidningen Näringsliv, in the supplement section “Time to Unite – a Greater […]
Expres2ion Biotechnologies is mentioned in the Danish newspaper Erhverv Nordsjælland. The article includes an interview with CEO Sten Klysner. The […]
Horsholm, Denmark, February 16, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]
Horsholm, Denmark, February 14, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, […]
On August 23 2016 ExpreS2ion Biotechnologies ApS, Horsholm, Denmark (”ExpreS2ion”) and the Francis Crick Institute, London, United Kingdom, announce that […]
The article “Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line […]
ExpreS2ion Biotechnologies’ scientists contributed to the research for the article by Thrane et al, ”Bacterial superglue enables easy development of […]
The talk titled “Development of Drosophilia S2 based sub-unit antigen vaccine production processes” will be held on Day 1 (Monday, […]
The meeting features the most exciting and challenging discussions on the industry’s most difficult applications including viral gene vectors and […]